- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05862844
Promise Women Project
November 29, 2023 updated by: Mark Dignan, PhD
PROMIS WOMAN Education Program : ImProving ceRvical Cancer preventiOn Methods Among Muslim AmerIcans WOMEN
The goal of this study is to develop and test an intervention program to improve cervical cancer prevention among Muslim American women. The main questions the investigators aim to answer are:
- Will the religiously tailored and culturally appropriate intervention program improve participants' knowledge and acceptance of cervical cancer prevention?
- Is the intervention program feasible to conduct and acceptable to participants?
Participants will be asked to:
- Attend focus group sessions to provide input on the development of educational materials.
- Complete pre- and post-intervention surveys to measure changes in knowledge and acceptance of cervical cancer prevention.
- Engage in the intervention program, which includes education and experiential practice/communication skills training.
- Provide feedback through satisfaction surveys. Researchers will compare participant outcomes before and after the intervention to assess its effectiveness. Additionally, the program's feasibility and acceptability will be evaluated based on enrollment rates, successful implementation, participant engagement, retention, and satisfaction.
Study Overview
Status
Completed
Conditions
Detailed Description
This project involves creating special educational materials for Muslim women to learn about cervical cancer prevention.
The investigators will engage in discussions with 10 Muslim women during dedicated group sessions to ensure the suitability of the materials.
They will also seek input from Muslim religious leaders.
Subsequently, they will conduct surveys before and after the program to assess the effectiveness of the materials in facilitating women's learning and comprehension of cervical cancer prevention.
To determine its efficacy and acceptability, the investigators will implement the program with an additional 20 women and gather their feedback.
The goal of this project is to promote the health and well-being of Muslim women by providing them with culturally and religiously sensitive information regarding cervical cancer prevention.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Asmaa Namoos, MD, MPH
- Phone Number: (757) 768-3512
- Email: asmaa.namoos@vcuhealth.org
Study Locations
-
-
Virginia
-
Hampton, Virginia, United States, 23666
- the Islamic center of Hampton
-
Contact:
- Asmaa M Namoos, MD,MPH
- Phone Number: 757-768-3512
- Email: asmaa.namoos@vcuhealth.org
-
Hampton, Virginia, United States, 23666
- the Peninsula Islamic Community Center
-
Contact:
- Asmaa M Namoos, MD,MPH
- Phone Number: 757-768-3512
- Email: asmaanamoos88@gmail.com
-
Henrico, Virginia, United States, 23228
- Islamic center of Henrico-Alfalah
-
Contact:
- Asmaa Namoos, MD,MPH
-
Richmond, Virginia, United States, 23060
- the Islamic center of Richmond
-
Contact:
- Asmaa M Namoos
- Phone Number: 757-768-3512
- Email: asmaa.namoos@vcuhealth.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Inclusion criteria:
- Female Muslim individuals above 18 years old.
- Able to speak and understand English.
- Have not had a hysterectomy.
- Have not had a cervical cancer diagnosis.
- Willing to participate in the educational program and undergo cervical cancer screening.
- Physically well, able to give consent form.
Exclusion Criteria:
- Under age 18
- Not Muslim
- Unable to provide consent
- Participated in a pilot study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: The single-arm trial with a pre- and post-test design
The Intervention Arm in the Promise Women Project evaluates a specific educational intervention program for Muslim women to promote cervical cancer prevention.
It involves a one-time, 90-minute culturally and religiously tailored educational session with 20 participants.
The session covers perceived risks of Human Papilloma Virus (HPV) infection, cervical cancer, and benefits of early screening and vaccination.
Pre- and post-intervention surveys measure changes in participants' knowledge.
This experimental arm assesses the intervention's effects on knowledge and acceptance of cervical cancer prevention.
|
The Intervention Arm involves a 90-minute educational session tailored to Muslim women.
They will learn about HPV infection risks, cervical cancer risks, and benefits of early screening and HPV vaccination.
Discussions cover transmission, consequences, risk factors (behaviors, infections, family history), and importance of early detection.
The session provides information on screening methods, check-ups, and HPV vaccine safety.
Participants actively engage in discussions, ask questions, and share thoughts.
The session empowers women with knowledge to make informed decisions about their health, promoting cervical cancer prevention.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of women who undergo cervical cancer screening.
Time Frame: 1 year
|
measured by tracking the number of women who schedule and attend
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of women enrolled
Time Frame: 1 year
|
Test the intervention program's feasibility as evidenced by meeting enrollment targets
|
1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of women that attend the education session
Time Frame: 1 year
|
Test the intervention program's acceptability as evidenced by session attendance
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Vanessa L Sheppard, PhD, Virginia Commonwealth University
- Study Director: Mark B Dignan, PhD, MPH, University of Kentucky
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 25, 2023
Primary Completion (Actual)
October 15, 2023
Study Completion (Actual)
October 15, 2023
Study Registration Dates
First Submitted
May 8, 2023
First Submitted That Met QC Criteria
May 8, 2023
First Posted (Actual)
May 17, 2023
Study Record Updates
Last Update Posted (Actual)
December 6, 2023
Last Update Submitted That Met QC Criteria
November 29, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Neoplasms, Squamous Cell
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Uterine Cervical Neoplasms
- Papilloma
Other Study ID Numbers
- HM20024502_VCU
- 3P30CA177558-10S1 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Cancer
-
University of California, San DiegoWithdrawnCervical Cancer | Cervical Cancer Stage | Cervical Cancer Stage IB2 | Cervical Cancer Stage IB1 | Cervical Cancer Stage I | Cervical Cancer Stage IB | Cervical Cancer Stage II | Cervical Cancer Stage IIa | Cervical Cancer, Stage IIB | Cervical Cancer, Stage III | Cervical Cancer Stage IIIB | Cervical Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterWithdrawnStage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage III Cervical Cancer FIGO 2018 | Stage IIIA Cervical Cancer FIGO... and other conditions
-
Abramson Cancer Center of the University of PennsylvaniaWithdrawnCervical Cancer | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingCervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Stage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IA Cervical Cancer | Stage IB Cervical Cancer | Stage IA1 Cervical Cancer | Stage IA2 Cervical Cancer | Stage IB1 Cervical Cancer | Stage IB2 Cervical Cancer | Stage IB3 Cervical CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical Cancer | Stage IIIA Cervical Cancer | Stage IIIB Cervical CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical CancerUnited States
-
Shanghai First Maternity and Infant HospitalNot yet recruitingCervical Cancer, Stage IIB | Cervical Cancer Stage IIIB | Cervical Cancer Stage IIIA | Cervical Cancer, Stage IVA
-
Institut de Cancérologie de LorraineCompletedCervical Adenocarcinoma | Stage IB Cervical Cancer | Stage III Cervical Cancer | Stage II Cervical CancerFrance
Clinical Trials on Promise women project (Promote Cervical Cancer Prevention Methods Among Muslim Women in Virginia )
-
University of SunderlandUniversity of GlasgowNot yet recruitingCervical Cancer | Breast Cancer | Bowel Cancer